University of California

University of Illinois

David A Nathanson

Michael E Jung

Nagichettiar Satyamurthy

Jennifer Marie Murphy

Caius G Radu

Jue Wang

Arnon Lavie

Raymond M Gipson

Zheng Li

Johannes Czernin

Peter M Clark

Jonathan Tsang

Timothy F Cloughesy

Gyudong Kim

Lorenz Urner

Hsiang-I Liao

The present disclosure relates to compounds, compositions and methods for treating cancer, including compounds that are capable of penetrating the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating cancer in the brain, including glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating cancers such as glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.

Compositions and methods for treating cancer

Provided herein are compounds that bind to dCK and methods for treating cancer.

Deoxycytidine kinase inhibitors

The invention provides compounds that bind to deoxycytidine kinase (dCK) and compositions including pharmaceutically acceptable compositions containing the compounds. The compounds are useful in treating diseases and disorders where dCK activity is implicated such as cancer and immune disorders. The compounds also find use in clinical methodologies including positron emission tomography (PET) imaging.

Deoxycytidine kinase binding compounds

Contact lens case

Growing community of inventors

Los Angeles, CA, United States of America

David A Nathanson